5,6,7,8-四氢-萘-1-磺酸酰胺 | 87473-78-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 5,6,7,8-四氢-萘-1-磺酸酰胺
• 英文名称: 5,6,7,8-tetrahydro-naphthalene-1-sulfonic acid amide
• 英文别名: 5,6,7,8-Tetrahydro-naphthalin-1-sulfonsaeure-amid；5,6,7,8-tetrahydro-1-naphthalenesulfonamide；5,6,7,8-tetrahydronaphthalene-1-sulfonamide
• CAS: 87473-78-7
• 化学式: C₁₀H₁₃NO₂S
• 分子量: 211.285
• InChiKey: YLIZJJSJRQYWRV-UHFFFAOYSA-N

物化性质

• 沸点：
  412.6±55.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢-萘-1-磺酸酰胺 、 alkaline earth salt of/the/ methylsulfuric acid 生成 3-sulfamoyl-phthalic acid
  参考文献：
  名称：

  v. Braun, Chemische Berichte, 1923, vol. 56, p. 2341

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 作用下， 生成 5,6,7,8-四氢-萘-1-磺酸酰胺
  参考文献：
  名称：

  Schroeter, Justus Liebigs Annalen der Chemie, 1922, vol. 426, p. 132

  摘要：

  DOI：

文献信息

• [EN] TDO2 INHIBITORS<br/>[FR] INHIBITEURS DE TDO2
  申请人：GENENTECH INC

  公开号：WO2017107979A1

  公开（公告）日：2017-06-29

  Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

  目前提供了细胞表达的TDO2的抑制剂及其药物组合物，用于调节色氨酸2,3双氧酶的活性；治疗免疫抑制；治疗受益于色氨酸降解抑制的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；以及治疗与癌症相关的肿瘤特异性免疫抑制。
• Herbicidal N-[heterocyclicaminocarbonyl]-1H-indene and
  申请人：E. I. DuPont de Nemours and Company

  公开号：US04465506A1

  公开（公告）日：1984-08-14

  N-[Heterocyclicaminocarbonyl]-1H-indene and tetrahydronaphthalene sulfonamides, such as 2,3-dihydro-N-[(4,6-dimethoxypyrimidin-2-yl)aminocarbonyl]-1H-indene-4-sul fonamide, are useful for the regulation of plant growth and as preemergent and postemergent herbicides.

  N-[杂环氨基甲酰基]-1H-茚烯和四氢萘磺胺类化合物，例如2,3-二氢-N-[(4,6-二甲氧基嘧啶-2-基)氨基甲酰基]-1H-茚烯-4-磺胺，可用于调节植物生长并作为除草剂的预发芽和后发芽剂。
• [EN] THIAZOLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS<br/>[FR] DÉRIVÉS DE THIAZOLE EN TANT QUE MODULATEURS DE NACHR ALPHA 7
  申请人：LUPIN LTD

  公开号：WO2013132380A1

  公开（公告）日：2013-09-12

  Disclosed is a compound of formula (I) wherein Y, Ring D, m and R1-R4 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as pharmaceutically acceptable salts, polymorphs, solvates, and isomers thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

  揭示的是一种化合物，其化学式为（I），其中Y、环D、m和R1-R4如本文所述，作为尼古丁型乙酰胆碱受体的调节剂，特别是α7亚型，在需要的受试者中使用，以及其药学上可接受的盐类、多型、溶剂合物和同分异构体，可单独使用或与适当的其他药物组合使用，以及含有这种化合物的药物组合物。还公开了一种制备这些化合物的方法及其在治疗中的预期用途，特别是在预防和治疗阿尔茨海默病、轻度认知障碍、老年性痴呆等疾病中的用途。
• [EN] SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER<br/>[FR] ACYLSULFONAMIDES SUBSTITUÉS POUR LE TRAITEMENT DU CANCER
  申请人：BROAD INST INC

  公开号：WO2022081807A1

  公开（公告）日：2022-04-21

  The present invention provides acyl sulfonamide compounds of general formula (I): in which R1, R2, R3, R4, R5, R6· Raand Rbare as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treatment and/or prophylaxis of diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.

  本发明提供了通式（I）的酰基磺酰胺化合物：其中，R1、R2、R3、R4、R5、R6·Ra和Rb如本文所述和定义，以及制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的药物组合物和组合物，以及使用该化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增生性疾病的药物组合物，作为唯一的活性成分或与其他活性成分组合使用，以及治疗和/或预防疾病的方法，特别是癌症，更特别是KAT6A和/或KAT6B局部扩增的癌症，其中该方法包括向需要该方法的受体中施用至少一种通式（I）的有效量化合物。
• 1,3-DIPOLAR CYCLOADDITION OF AZIDES TO ALKYNES
  申请人：Musa Osama M.

  公开号：US20100121022A1

  公开（公告）日：2010-05-13

  A process for the bulk polymerization, in the absence of any solvent, of a reactant containing azide functionality and a reactant containing a terminal alkyne functionality, in the presence of Cu (I) catalyst or in the presence of a Cu(II) catalyst without a reducing agent, is described. Polymerization can be achieved at temperatures less than 100° C., which is suitable for low temperature cures. A controlled synthesis for low molecular weight oligomers is disclosed.

  本发明涉及一种无溶剂的大量聚合过程，其中包含一种含有叠氮官能团的反应物和一种含有末端炔基官能团的反应物，在存在Cu（I）催化剂或Cu（II）催化剂且无还原剂的情况下进行。可以在低于100℃的温度下实现聚合，适用于低温固化。本发明还公开了低分子量寡聚物的可控合成方法。